Prevalence and predictive factors of depressive symptoms among primiparae in antenatal care: A cross‐sectional study in the new families programme

Øygarden, Anne-Martha Utne; Småstuen, Milada Cvancarova; Abudayya, Abdallah; Glavin, Kari; Saether, Kristin Marie; Solberg, Beate; Brekke, Malene; Strøm, Benedicte Sørensen

doi:10.1111/jocn.16608

Cited by 2 publications

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Maternal antibiotic exposure and the risk of developing antenatal or postpartum depression: The Maternal Experience Study protocol

Pouranayatihosseinabad,

Taylor,

Hawrelak

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Limited epidemiological evidence suggests a link between antibiotic use and the development of depression. This study seeks to investigate this association in-depth, using a cohort of pregnant individuals. The primary aim is to explore any association between antibiotic use during pregnancy, delivery, and within 12 months postpartum, and the development of antenatal and/or postpartum depression. Methods A national prospective, observational, longitudinal cohort study has been designed to examine the relationship between the use of antibiotics during pregnancy and the development of antenatal depression up to the third trimester (32-42 weeks), as well as the use of antibiotics during pregnancy and within 12 months postpartum and the development of depression during the postpartum period. The development of depression is considered as either a diagnosis by a medical doctor and/or a scoring 13 or higher on the Edinburgh Postnatal Depression Scale. Data will be collected using online surveys, during the third trimester, and at 6 weeks, 6 months, and 12 months postpartum. These surveys include a wide range of variables previously identified as being associated with antenatal and postpartum depression (such as level of social support, history of depression, and intimate partner abuse), as well as antibiotic and probiotic use. The impact of the COVID-19 pandemic on both participants’ pregnancy experience and their mental health will also be explored. Recruitment began in August 2021, using a combination of online paid and unpaid advertisements, as well as distribution of the study flyer in relevant clinics and public spaces. It is anticipated that data collection will be completed in early 2024. Discussion This study will provide a much-needed update on the prevalence of depression during pregnancy and postpartum, and its associated factors. It will also, for the first time, comprehensively explore the potential association between antibiotic use during pregnancy and up to 12 months postpartum and the development of depression. Additionally, it will provide a better understanding of the mental health impacts of the COVID-19 pandemic on pregnant individuals in Australia.

show abstract

Maternal antibiotic exposure and the risk of developing antenatal or postpartum depression: The Maternal Experience Study protocol

Pouranayatihosseinabad,

Taylor,

Hawrelak

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Maternal Antibiotic Exposure and the Risk of Developing Antenatal or Postpartum Depressive Symptoms: The Maternal Experience Study Protocol

Pouranayatihosseinabad,

Taylor,

Hawrelak

et al. 2023

MPs

View full text Add to dashboard Cite

Limited epidemiological evidence suggests a link between antibiotic use and developing depression. This study seeks to investigate this association in depth, using a cohort of pregnant individuals. The primary aim is to explore any association between the use of antibiotics during pregnancy and the development of antenatal depressive symptoms up to the third trimester, as well as the use of antibiotics during pregnancy and within 12 months postpartum and the development of postpartum depressive symptoms. A national prospective, observational, longitudinal cohort study has been designed to examine these relationships. A sample size of 1500 pregnant individuals has been sought for this study, assuming 10 potential predictor variables (including antibiotic use) in the final multiple logistic regression model and allowing for a 30% drop-out rate. The development of depressive symptoms is considered either a diagnosis by a medical doctor and/or a scoring 13 or higher on the Edinburgh Postnatal Depression Scale. Data will be collected during the third trimester and at 6 weeks, 6 months, and 12 months postpartum. These surveys include variables previously identified as associated with antenatal and postpartum depression (e.g., level of social support, experience of intimate partner abuse, and obstetric complications), as well as antibiotic and probiotic use. This study will provide an update on the prevalence of the symptoms of depression during pregnancy and postpartum and its associated risk factors. It will also, for the first time, comprehensively explore the potential association between antibiotic use during pregnancy and up to 12 months postpartum and the development of depressive symptoms.

show abstract

Prevalence and predictive factors of depressive symptoms among primiparae in antenatal care: A cross‐sectional study in the new families programme

Cited by 2 publications

References 53 publications

Maternal antibiotic exposure and the risk of developing antenatal or postpartum depression: The Maternal Experience Study protocol

Maternal antibiotic exposure and the risk of developing antenatal or postpartum depression: The Maternal Experience Study protocol

Maternal Antibiotic Exposure and the Risk of Developing Antenatal or Postpartum Depressive Symptoms: The Maternal Experience Study Protocol

Contact Info

Product

Resources

About